

PubMed

Format: Summary Sort by: Most Recent Per page: 100

Search results

Items: 71

- [Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.](#)
1. Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, **Lebwohl D**, Baselga J.
J Clin Oncol. 2016 Feb 10;34(5):419-26. doi: 10.1200/JCO.2014.60.1971. Epub 2015 Oct 26.
PMID: 26503204 [Free PMC Article](#)
- [Everolimus plus exemestane in postmenopausal patients with HR\(+\) breast cancer: BOLERO-2 final progression-free survival analysis.](#)
2. Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, **Lebwohl D**, Rugo HS.
Adv Ther. 2013 Oct;30(10):870-84. doi: 10.1007/s12325-013-0060-1. Epub 2013 Oct 25. Erratum in: Adv Ther. 2014 Sep;31(9):1008-9.
PMID: 24158787 [Free PMC Article](#)
- [Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.](#)
3. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahnoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, **Lebwohl D**, Van Cutsem E.
J Clin Oncol. 2013 Nov 1;31(31):3935-43. doi: 10.1200/JCO.2012.48.3552. Epub 2013 Sep 16.
PMID: 24043745
- [Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.](#)
4. **Lebwohl D**, Anak O, Sahnoud T, Klimovsky J, Elmroth I, Haas T, Posluszny J, Saletan S, Berg W.
Ann N Y Acad Sci. 2013 Jul;1291:14-32. doi: 10.1111/nyas.12122. Epub 2013 May 9. Review.
PMID: 23659703
- [Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.](#)
5. Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahnoud T, **Lebwohl D**, Campone M, Pritchard KI.
J Natl Cancer Inst. 2013 May 1;105(9):654-63. doi: 10.1093/jnci/djt026. Epub 2013 Feb 19.
PMID: 23425564
- [Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis \(EXIST-2\): a multicentre, randomised, double-blind, placebo-controlled trial.](#)
6. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahnoud T, Shah G, Lincy J, **Lebwohl D**, Budde K.
Lancet. 2013 Mar 9;381(9869):817-24.
PMID: 23312829

- [Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex \(EXIST-1\): a multicentre, randomised, placebo-controlled phase 3 trial.](#)
7. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, **Lebwohl D**, Sahnoud T, Jozwiak S.
Lancet. 2013 Jan 12;381(9861):125-32. doi: 10.1016/S0140-6736(12)61134-9. Epub 2012 Nov 14. Erratum in: Lancet. 2013 Jan 12;381(9861):116.
PMID: 23158522
- [Correcting overall survival for the impact of crossover via a rank-preserving structural failure time \(RPSFT\) model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma.](#)
8. Korhonen P, Zuber E, Branson M, Hollaender N, Yateman N, Katiskalahti T, **Lebwohl D**, Haas T.
J Biopharm Stat. 2012;22(6):1258-71. doi: 10.1080/10543406.2011.592233.
PMID: 23075021
- [Vascular density analysis in colorectal cancer patients treated with vatalanib \(PTK787/ZK222584\) in the randomised CONFIRM trials.](#)
9. Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, **Lebwohl D**, Jalava T, Laurent D, Meinhardt G, Harris AL; Tumour and Angiogenesis Research Group.
Br J Cancer. 2012 Sep 25;107(7):1044-50. doi: 10.1038/bjc.2012.369. Epub 2012 Aug 21.
PMID: 22910317 **Free PMC Article**
- [Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 \(vatalanib\).](#)
10. Wilson PM, Yang D, Azuma M, Shi MM, Danenberg KD, **Lebwohl D**, Sherrod A, Ladner RD, Zhang W, Danenberg PV, Trarbach T, Folprecht G, Meinhardt G, Lenz HJ.
Pharmacogenomics J. 2013 Oct;13(5):410-6. doi: 10.1038/tpj.2012.23. Epub 2012 Jun 5.
PMID: 22664478
- [Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.](#)
11. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahnoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, **Lebwohl D**, Hortobagyi GN.
N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7.
PMID: 22149876 **Free Article**
- [Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome \(RADIANT-2\): a randomised, placebo-controlled, phase 3 study.](#)
12. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, **Lebwohl D**, Jehl V, Wolin EM, Öberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group.
Lancet. 2011 Dec 10;378(9808):2005-2012. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25.
PMID: 22119496
- [TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.](#)
13. Grimminger PP, Shi M, Barrett C, **Lebwohl D**, Danenberg KD, Brabender J, Vigen CL, Danenberg PV, Winder T, Lenz HJ.
Pharmacogenomics J. 2012 Oct;12(5):404-11. doi: 10.1038/tpj.2011.29. Epub 2011 Jul 26.
PMID: 21788964
- [Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 \(vatalanib\) antiangiogenic therapy.](#)
- 14.

Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, **Lebwohl D**, Jalava T, Laurent D, Meinhardt G, Harris AL.

Clin Cancer Res. 2011 Jul 15;17(14):4892-900. doi: 10.1158/1078-0432.CCR-10-2918. Epub 2011 Jun 1.

PMID: 21632858 **Free PMC Article**

- [Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.](#)
15. Hecht JR, Trarbach T, Hainsworth JD, Major P, Jäger E, Wolff RA, Lloyd-Salvant K, Bodoky G, Pendergrass K, Berg W, Chen BL, Jalava T, Meinhardt G, Laurent D, **Lebwohl D**, Kerr D.
J Clin Oncol. 2011 May 20;29(15):1997-2003. doi: 10.1200/JCO.2010.29.4496. Epub 2011 Apr 4.
PMID: 21464406
- [Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.](#)
16. Van Cutsem E, Bajetta E, Valle J, Köhne CH, Hecht JR, Moore M, Germond C, Berg W, Chen BL, Jalava T, **Lebwohl D**, Meinhardt G, Laurent D, Lin E.
J Clin Oncol. 2011 May 20;29(15):2004-10. doi: 10.1200/JCO.2010.29.5436. Epub 2011 Apr 4.
PMID: 21464401
- [Research and innovation in the development of everolimus for oncology.](#)
17. **Lebwohl D**, Thomas G, Lane HA, O'Reilly T, Escudier B, Yao JC, Pavel M, Franz D, Berg W, Baladi JF, Stewart J, Motzer RJ.
Expert Opin Drug Discov. 2011 Mar;6(3):323-38. doi: 10.1517/17460441.2011.558079. Epub 2011 Feb 17.
PMID: 22647206
- [Everolimus for advanced pancreatic neuroendocrine tumors.](#)
18. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, **Lebwohl D**, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group.
N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.
PMID: 21306238 **Free PMC Article**
- [A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.](#)
19. Drevs J, Medinger M, Mross K, Fuxius S, Hennig J, Buechert M, Thomas A, Unger C, Chen BL, **Lebwohl D**, Laurent D.
Anticancer Res. 2010 Jun;30(6):2335-9.
PMID: 20651389
- [Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.](#)
20. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruzniewski P, Hoosen S, St Peter J, Haas T, **Lebwohl D**, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B.
J Clin Oncol. 2010 Jan 1;28(1):69-76. doi: 10.1200/JCO.2009.24.2669. Epub 2009 Nov 23.
PMID: 19933912 **Free PMC Article**
- [Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.](#)
21. Yuan R, Kay A, Berg WJ, **Lebwohl D**.
J Hematol Oncol. 2009 Oct 27;2:45. doi: 10.1186/1756-8722-2-45. Review.
PMID: 19860903 **Free PMC Article**

- [Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.](#)
22. **Lebwohl D**, Kay A, Berg W, Baladi JF, Zheng J.
Cancer J. 2009 Sep-Oct;15(5):386-94. doi: 10.1097/PPO.0b013e3181b9c5ec. Review.
PMID: 19826358
- [Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.](#)
23. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, **Lebwohl D**, Ravaud A; RECORD-1 Study Group.
Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22.
PMID: 18653228
- [Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.](#)
24. Awada A, Piccart MJ, Jones SF, Peck RA, Gil T, **Lebwohl D**, Wu CY, Burris HA 3rd.
Cancer Chemother Pharmacol. 2009 Feb;63(3):417-25. doi: 10.1007/s00280-008-0751-5. Epub 2008 Apr 29.
PMID: 18446338
- [Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.](#)
25. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, **Lebwohl D**, Baselga J.
J Clin Oncol. 2008 Apr 1;26(10):1603-10. doi: 10.1200/JCO.2007.14.5482. Epub 2008 Mar 10. Erratum in: J Clin Oncol. 2010 Dec 20;28(36):5350.
PMID: 18332469
- [Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 \(panobinostat\).](#)
26. Zhang L, **Lebwohl D**, Masson E, Laird G, Cooper MR, Prince HM.
J Clin Oncol. 2008 Jan 10;26(2):332-3; discussion 333-4. doi: 10.1200/JCO.2007.14.7249. No abstract available. Erratum in: J Clin Oncol. 2008 Apr 20;26(12):2066.
PMID: 18182676
- [Phase II clinical trial of ixabepilone \(BMS-247550\), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.](#)
27. Thomas E, Tabernero J, Fornier M, Conté P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, **Lebwohl D**, Martin M.
J Clin Oncol. 2007 Aug 10;25(23):3399-406. Epub 2007 Jul 2.
PMID: 17606975
- [Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.](#)
28. Vansteenkiste J, Lara PN Jr, Le Chevalier T, Breton JL, Bonomi P, Sandler AB, Socinski MA, Delbaldo C, McHenry B, **Lebwohl D**, Peck R, Edelman MJ.
J Clin Oncol. 2007 Aug 10;25(23):3448-55. Epub 2007 Jul 2. Erratum in: J Clin Oncol. 2007 Nov 20;25(33):5339. Edelman, Mark [corrected to Edelman, Martin J].
PMID: 17606973
- [Phase II clinical trial of ixabepilone \(BMS-247550\), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.](#)
29. Roché H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, Kerbrat P, Delord JP, Vahdat L, Peck R, **Lebwohl D**, Ezzeddine R, Curé H.
J Clin Oncol. 2007 Aug 10;25(23):3415-20. Epub 2007 Jul 2.

PMID: 17606972

- [Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 \(Everolimus\)-letrozole clinical program.](#)
30. Lane HA, **Lebwohl D**.
Semin Oncol. 2006 Apr;33(2 Suppl 7):S18-25. Review.
PMID: 16730273
- [A multi-center phase II study of BMS-247550 \(Ixabepilone\) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane.](#)
31. Ajani JA, Safran H, Bokemeyer C, Shah MA, Lenz HJ, Van Cutsem E, Burris HA 3rd, **Lebwohl D**, Mullaney B.
Invest New Drugs. 2006 Sep;24(5):441-6.
PMID: 16586011
- [Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor \(VEGF\) receptor inhibitor, PTK787/ZK 222584 \(PTK/ZK\): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.](#)
32. Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, Drevs J, **Lebwohl D**, Wood J, McSheehy PM.
Cancer Chemother Pharmacol. 2006 Jun;57(6):761-71. Epub 2005 Sep 20.
PMID: 16172907
- [Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.](#)
33. Mross K, Drevs J, Müller M, Medinger M, Marmé D, Hennig J, Morgan B, **Lebwohl D**, Masson E, Ho YY, Günther C, Laurent D, Unger C.
Eur J Cancer. 2005 Jun;41(9):1291-9.
PMID: 15939265
- [Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.](#)
34. Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, Van Erps P, Theodore C, Koriakine O, Oliver T, **Lebwohl D**, Debois M, Zurlo A, Collette L; Genitourinary Tract Group of the EORTC.
Oncology. 2005;68(1):2-9. Epub 2005 Feb 28.
PMID: 15741753
- [Soluble markers for the assessment of biological activity with PTK787/ZK 222584 \(PTK/ZK\), a vascular endothelial growth factor receptor \(VEGFR\) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.](#)
35. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, **Lebwohl D**, Dugan M, Marmé D.
Ann Oncol. 2005 Apr;16(4):558-65. Epub 2005 Feb 10.
PMID: 15705616
- [Phase II study of oral bis \(aceto\) ammine dichloro \(cyclohexamine\) platinum \(IV\) \(JM-216, BMS-182751\) given daily x 5 in hormone refractory prostate cancer \(HRPC\).](#)
36. Latif T, Wood L, Connell C, Smith DC, Vaughn D, **Lebwohl D**, Peereboom D.
Invest New Drugs. 2005 Jan;23(1):79-84.
PMID: 15528984 **Free Article**
- [Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.](#)
37.

Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, **Lebwohl D**, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD.
Blood. 2005 Jan 1;105(1):54-60. Epub 2004 Sep 2.
PMID: 15345597 **Free Article**

[PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.](#)

38. Stone RM, De Angelo J, Galinsky I, Estey E, Klimek V, Grandin W, **Lebwohl D**, Yap A, Cohen P, Fox E, Neuberg D, Clark J, Gilliland DG, Griffin JD.
Ann Hematol. 2004;83 Suppl 1:S89-90. No abstract available.
PMID: 15124689

[Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.](#)

39. Mani S, McDaid H, Hamilton A, Hochster H, Cohen MB, Khabelle D, Griffin T, **Lebwohl DE**, Liebes L, Muggia F, Horwitz SB.
Clin Cancer Res. 2004 Feb 15;10(4):1289-98.
PMID: 14977827 **Free Article**

[Phase III study of N,N-diethyl-2-\[4-\(phenylmethyl\) phenoxy\]ethanamine \(BMS-217380-01\) combined with](#)

40. [doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.](#)
Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Dancey J, Pearce L, MacNeil M, Marlin S, **Lebwohl D**, Voi M, Pritchard K; National Cancer Institute of Canada Clinical Trials Group Study MA.19.
J Clin Oncol. 2004 Jan 15;22(2):269-76.
PMID: 14722035

[Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.](#)

41. Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, Widemann B, Davis L, Damle B, Sonnichsen D, **Lebwohl D**, Bates S, Kotz H, Fojo T.
J Clin Oncol. 2003 May 1;21(9):1866-73.
PMID: 12721265

[Phase I study of JM-216 \(an oral platinum analogue\) in combination with paclitaxel in patients with advanced malignancies.](#)

42. Jones S, Hainsworth J, Burris HA 3rd, Thompson D, Raefsky E, Johnson V, Calvert S, Bulanhagui C, **Lebwohl D**, Greco FA.
Invest New Drugs. 2002 Feb;20(1):55-61.
PMID: 12008664

[A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.](#)

43. Trudeau M, Stuart G, Hirte H, Drouin P, Plante M, Bessette P, Dulude H, **Lebwohl D**, Fisher B, Seymour L.
Gynecol Oncol. 2002 Feb;84(2):327-31.
PMID: 11812095

[Radiopotentiality by the oral platinum agent, JM216: role of repair inhibition.](#)

44. Amorino GP, Freeman ML, Carbone DP, **Lebwohl DE**, Choy H.
Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):399-405.
PMID: 10760436

[New developments in chemotherapy of advanced breast cancer.](#)

45. **Lebwohl DE**, Canetta R.

Ann Oncol. 1999;10 Suppl 6:139-46. Review.
PMID: 10676565

- [5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.](#)
46. Hudis C, Fornier M, Riccio L, **Lebwohl D**, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L. J Clin Oncol. 1999 Apr;17(4):1118.
PMID: 10561169

- [Phase II trial of N,N-diethyl-2-\[4-\(phenylmethyl\)phenoxy\]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study.](#)
47. Khoo K, Brandes L, Reyno L, Arnold A, Dent S, Vandenberg T, **Lebwohl D**, Fisher B, Eisenhauer E. J Clin Oncol. 1999 Nov;17(11):3431-7.
PMID: 10550138

- [Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.](#)
48. Hudis C, Seidman A, Baselga J, Raptis G, **Lebwohl D**, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JP, Surbone A, Uhlenhopp M, Riedel E, Yao TJ, Norton L. J Clin Oncol. 1999 Jan;17(1):93-100.
PMID: 10458222

- [A phase I study of oral uracil/ftorafur \(UFT\) plus leucovorin and bis-acetato-amine-dichloro-cyclohexylamine-platinum IV \(JM-216\) each given over 14 days every 28 days.](#)
49. DeMario MD, Ratain MJ, Vogelzang NJ, Mani S, Vokes EE, Fleming GF, Melton K, Johnson S, Benner S, **Lebwohl D**. Cancer Chemother Pharmacol. 1999;43(5):385-8.
PMID: 10100593

- [Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.](#)
50. **Lebwohl D**, Canetta R. Eur J Cancer. 1998 Sep;34(10):1522-34. Review.
PMID: 9893623

- [Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.](#)
51. Hudis C, Riccio L, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, **Lebwohl D**, Moynahan M, Raptis G, Surbone A, Sklarin N, Yao TJ, Keefe D, Norton L. Cancer Invest. 1998;16(2):67-71. No abstract available.
PMID: 9512671

- [Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.](#)
52. Hudis C, Seidman A, Raptis G, Fennelly D, Gilewski T, Baselga J, Theodoulou M, Sklarin N, Moynahan M, Surbone A, Currie V, **Lebwohl D**, Uhlenhopp M, Crown J, Norton L. Semin Oncol. 1996 Feb;23(1 Suppl 1):58-64.
PMID: 8629040

- [Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.](#)
53. Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, **Lebwohl DE**, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L. J Clin Oncol. 1996 Jan;14(1):58-65.
PMID: 8558221

- [Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.](#)
54. Hudis CA, Seidman AD, Baselga J, Raptis G, **Lebwohl D**, Gilewski T, Currie V, Moynahan ME, Sklarin N, Fennelly D, et al.
Semin Oncol. 1995 Dec;22(6 Suppl 15):18-23.
PMID: 8643965
- [Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells.](#)
55. Bentele JM, **Lebwohl DE**, Cullen KJ, Rubin MS, Rosen N, Mendelsohn J, Miller WH Jr.
J Cell Physiol. 1995 Oct;165(1):212-21.
PMID: 7559803
- [Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases.](#)
56. Sepp-Lorenzino L, Ma Z, **Lebwohl DE**, Vinitsky A, Rosen N.
J Biol Chem. 1995 Jul 14;270(28):16580-7.
PMID: 7622464 **Free Article**
- [Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line.](#)
57. Sepp-Lorenzino L, Rosen N, **Lebwohl DE**.
Cell Growth Differ. 1994 Oct;5(10):1077-83.
PMID: 7848909 **Free Article**
- [Taxol \(paclitaxel\) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer.](#)
58. Seidman AD, Norton L, Reichman BS, Crown JP, Yao TJ, Hakes TB, **Lebwohl DE**, Gilewski TA, Hudis CA, Surbone A, et al.
Oncology. 1994 Oct;51 Suppl 1:33-9.
PMID: 7526308
- [A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line.](#)
59. **Lebwohl DE**, Muise-Helmericks R, Sepp-Lorenzino L, Serve S, Timaul M, Bol R, Borgen P, Rosen N.
Oncogene. 1994 Jul;9(7):1925-9.
PMID: 8208539
- [Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients.](#)
60. Anelli TF, Anelli A, Tran KN, **Lebwohl DE**, Borgen PI.
Cancer. 1994 Jul 1;74(1):74-7.
PMID: 8004585 **Free Article**
- [Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report.](#)
61. Reichman BS, Seidman AD, Crown JP, Heelan R, Yao TJ, Hakes TB, **Lebwohl DE**, Gilewski TA, Surbone A, Currie V, et al.
Ann N Y Acad Sci. 1993 Nov 30;698:398-402. No abstract available.
PMID: 7506506
- [Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.](#)
62. Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, **Lebwohl DE**, Gilewski TA, Surbone A, Currie V, Hudis CA, et al.
J Clin Oncol. 1993 Oct;11(10):1943-51.

PMID: 7691998

- [Preliminary experience with paclitaxel \(Taxol\) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.](#)
63. Seidman AD, Norton L, Reichman BS, Crown JP, Yao TJ, Heelan R, Hakes TB, **Lebwohl DE**, Gilewski TA, Surbone A, et al.
Semin Oncol. 1993 Aug;20(4 Suppl 3):40-5.
PMID: 7688145
- [Phase II trial of carboplatin and etoposide in metastatic breast cancer.](#)
64. Crown J, Hakes T, Reichman B, **Lebwohl D**, Gilewski T, Surbone A, Currie V, Yao TJ, Hudis C, Seidman A, et al.
Cancer. 1993 Feb 15;71(4):1254-7.
PMID: 8435802 **Free Article**
- [Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report.](#)
65. Seidman AD, Reichman BS, Crown JP, Yao TJ, Heelan R, Hakes TB, **Lebwohl DE**, Gilewski TA, Surbone A, Currie V, et al.
J Natl Cancer Inst Monogr. 1993;(15):171-5.
PMID: 7517153
- [Expression of inducible membrane-anchored insulin receptor kinase enhances deoxyglucose uptake.](#)
66. **Lebwohl DE**, Nunez I, Chan M, Rosen OM.
J Biol Chem. 1991 Jan 5;266(1):386-90.
PMID: 1845969 **Free Article**
- [Polylysine activates and alters the divalent cation requirements of the insulin receptor protein tyrosine kinase.](#)
67. Rosen OM, **Lebwohl DE**.
FEBS Lett. 1988 Apr 25;231(2):397-401.
PMID: 3360145 **Free Article**
- [Synthesis, purification, and characterization of the cytoplasmic domain of the human insulin receptor using a baculovirus expression system.](#)
68. Herrera R, **Lebwohl D**, Garcia de Herreros A, Kallen RG, Rosen OM.
J Biol Chem. 1988 Apr 25;263(12):5560-8.
PMID: 2451671 **Free Article**
- [Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin.](#)
69. Chou CK, Dull TJ, Russell DS, Gherzi R, **Lebwohl D**, Ullrich A, Rosen OM.
J Biol Chem. 1987 Feb 5;262(4):1842-7.
PMID: 3100537 **Free Article**
- [The T lymphocyte response to cytochrome C. III. Relationship of the fine specificity of antigen recognition to major histocompatibility complex genotype.](#)
70. Matis LA, Hedrick SM, Hannum C, Ultee ME, **Lebwohl D**, Margoliash E, Solinger AM, Lerner EA, Schwartz RH.
J Immunol. 1982 Jun;128(6):2439-46. No abstract available.
PMID: 6176634
- [The T lymphocyte response to cytochrome c--II. Molecular characterization of a pigeon cytochrome c determinant recognized by proliferating T lymphocytes of the B10.A mouse.](#)
71. Ultee ME, Margoliash E, Lipkowski A, Flouret G, Solinger AM, **Lebwohl D**, Matis LA, Chen C, Schwartz RH.

7/27/2017

lebwohl-de OR lebwohl-d NOT lebwohl-dj - PubMed - NCBI

Mol Immunol. 1980 Jul;17(7):809-22. No abstract available.

PMID: 6163966

[Back to top](#)